Nektar Therapeutics Stock Revenue
| NKTR Stock | USD 0.89 0.02 2.20% |
Nektar Therapeutics fundamentals help investors to digest information that contributes to Nektar Therapeutics' financial success or failures. It also enables traders to predict the movement of Nektar Stock. The fundamental analysis module provides a way to measure Nektar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nektar Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 103.6 M | 162.3 M |
Nektar | Revenue |
Nektar Therapeutics Company Revenue Analysis
Nektar Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Nektar Therapeutics Revenue | 90.12 M |
Most of Nektar Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nektar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Nektar
Projected quarterly revenue analysis of Nektar Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Nektar Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Nektar Therapeutics' stock price.
Nektar Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Nektar Therapeutics is extremely important. It helps to project a fair market value of Nektar Stock properly, considering its historical fundamentals such as Revenue. Since Nektar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nektar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nektar Therapeutics' interrelated accounts and indicators.
| 0.21 | 0.18 | -0.01 | 0.35 | 0.61 | ||
| 0.21 | 0.08 | -0.28 | 0.99 | 0.56 | ||
| 0.18 | 0.08 | -0.84 | 0.12 | 0.53 | ||
| -0.01 | -0.28 | -0.84 | -0.27 | -0.5 | ||
| 0.35 | 0.99 | 0.12 | -0.27 | 0.63 | ||
| 0.61 | 0.56 | 0.53 | -0.5 | 0.63 |
Click cells to compare fundamentals
Nektar Revenue Historical Pattern
Today, most investors in Nektar Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nektar Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Nektar Therapeutics revenue as a starting point in their analysis.
Nektar Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Nektar Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Nektar Therapeutics reported 90.12 M of revenue. This is 98.82% lower than that of the Pharmaceuticals sector and 87.87% lower than that of the Health Care industry. The revenue for all United States stocks is 99.04% higher than that of the company.
Nektar Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nektar Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nektar Therapeutics could also be used in its relative valuation, which is a method of valuing Nektar Therapeutics by comparing valuation metrics of similar companies.Nektar Therapeutics is currently under evaluation in revenue category among its peers.
Nektar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Nektar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nektar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nektar Therapeutics' value.| Shares | State Street Corp | 2024-09-30 | 3.3 M | Renaissance Technologies Corp | 2024-09-30 | 3.3 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 2.8 M | Monaco Asset Management | 2024-09-30 | 2 M | Goldman Sachs Group Inc | 2024-09-30 | 1.8 M | Woodline Partners Lp | 2024-09-30 | 1.7 M | Shay Capital Llc | 2024-09-30 | 1.6 M | Two Sigma Advisers, Llc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-09-30 | 16 M | Deep Track Capital, Lp | 2024-09-30 | 15.9 M |
Nektar Fundamentals
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.81) % | ||||
| Operating Margin | (1.42) % | ||||
| Current Valuation | 28.3 M | ||||
| Shares Outstanding | 184.46 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 76.59 % | ||||
| Number Of Shares Shorted | 4.35 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 3.37 X | ||||
| Price To Sales | 1.77 X | ||||
| Revenue | 90.12 M | ||||
| Gross Profit | 63.15 M | ||||
| EBITDA | (243.11 M) | ||||
| Net Income | (276.06 M) | ||||
| Cash And Equivalents | 546.39 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 117.78 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 7.14 X | ||||
| Book Value Per Share | 0.27 X | ||||
| Cash Flow From Operations | (192.61 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (0.84) X | ||||
| Price To Earnings To Growth | 3.22 X | ||||
| Target Price | 4.56 | ||||
| Number Of Employees | 137 | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 164.54 M | ||||
| Total Asset | 398.03 M | ||||
| Retained Earnings | (3.48 B) | ||||
| Working Capital | 279.43 M | ||||
| Current Asset | 350.05 M | ||||
| Current Liabilities | 61.25 M | ||||
| Net Asset | 398.03 M |
About Nektar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nektar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nektar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nektar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Nektar Stock
| 0.63 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.84 | GSK | GlaxoSmithKline PLC ADR Sell-off Trend | PairCorr |
| 0.86 | NVS | Novartis AG ADR | PairCorr |
Moving against Nektar Stock
| 0.69 | MBFJF | Mitsubishi UFJ Financial | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.39 | GILD | Gilead Sciences | PairCorr |
| 0.35 | LH | Laboratory | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.